NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

萊姆病(LD) - 市場洞察,流行病學,市場預測 ∼2027年

Lyme disease (LD) - Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 751748
出版日期 按訂單生產 內容資訊 英文 150 Pages
商品交期: 10個工作天內
價格
萊姆病(LD) - 市場洞察,流行病學,市場預測 ∼2027年 Lyme disease (LD) - Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 150 Pages
簡介

本報告提供主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的萊姆病(LD)市場相關調查,總括性彙整疾病概要和現行的治療方法,新藥的簡介,主要7個國家的市場趨勢,流行病學的預測,未滿足需求,各治療藥物的市場規模的轉變預測,市場成長要素及障礙等資訊。

目錄

第1章 重要的洞察

第2章 萊姆病(LD)市場概要

  • 市場佔有率(實際成果值)
  • 市場佔有率(預測值)

第3章 疾病背景和概要:萊姆病(LD)

  • 簡介
  • 微生物學
  • 傳播
  • 臨床症狀
    • 早期局部存在性疾病
    • 早期傳播疾病
    • 晚期發病性疾病
  • 萊姆病(LD)的風險
  • 病因
  • 診斷
  • 誤診
  • 預後
  • 治療後萊姆病症候群(PTLDS)
  • 預防

第4章 流行病學和患者人口

  • 主要的觀察

第5章 主要7個國家的萊姆病(LD)市場

    • 主要7個國家的整體患病數
    • 主要7個國家的整體罹患數

第6章 萊姆病(LD)的各國流行病學

  • 美國
    • 前提和根據
    • 整體罹患數
    • 罹患數:性別
    • 急性·慢性萊姆病(LD)的整體罹患數
    • 診斷數:性別
  • 歐盟5國
  • 德國
    • 前提和根據
    • 整體罹患數
    • 罹患數:性別
    • 急性·慢性萊姆病(LD)的整體罹患數
    • 診斷數:性別
  • 法國
    • 前提和根據
    • 整體罹患數
    • 罹患數:性別
    • 急性·慢性萊姆病(LD)的整體罹患數
    • 診斷數:性別
  • 義大利
    • 前提和根據
    • 整體罹患數
    • 罹患數:性別
    • 急性·慢性萊姆病(LD)的整體罹患數
    • 診斷數:性別
  • 西班牙
    • 前提和根據
    • 整體罹患數
    • 罹患數:性別
    • 急性·慢性萊姆病(LD)的整體罹患數
    • 診斷數:性別
  • 日本
    • 前提和根據
    • 整體罹患數
    • 罹患數:性別
    • 急性·慢性萊姆病(LD)的整體罹患數
    • 診斷數:性別

第7章 治療

  • 初期侷限性萊姆病(不滿30日)
  • 早期傳播萊姆病(不滿3個月)
  • 晚期萊姆病(3個月以上)

第8章 美國的萊姆病(LD)相關指南

第9章 歐洲的萊姆病(LD)相關指南

第10章 未滿足需求

第11章 新藥

  • 關鍵交叉競爭
  • VLA15:Valneva
    • 產品說明
    • 其他開發活動
    • 臨床開發
    • 安全性和有效性
    • 優點與缺點
    • 產品的簡介

第12章 市場分析主要7個國家

  • 主要的觀察
  • 萊姆病(LD)的市場規模

第13章 美國市場預測

  • 萊姆病(LD)的整體市場規模
  • 市場規模:各治療藥物

第14章 歐盟5國市場預測

  • 德國
    • 萊姆病(LD)的整體市場規模
    • 市場規模:各治療藥物
  • 法國
    • 萊姆病(LD)的整體市場規模
    • 市場規模:各治療藥物
  • 義大利
    • 萊姆病(LD)的整體市場規模
    • 市場規模:各治療藥物
  • 西班牙
    • 萊姆病(LD)的整體市場規模
    • 市場規模:各治療藥物
  • 英國
    • 萊姆病(LD)的整體市場規模
    • 市場規模:各治療藥物

第15章 日本市場預測

  • 整體市場規模
  • 市場規模:各治療藥物

第16章 市場成長要素

第17章 市場障礙

第18章 附錄

  • 調查方法

第19章 DelveInsight的服務內容

第20章 免責聲明

第21章 關於DelveInsight

目錄
Product Code: DIMI0484

DelveInsight's "Lyme disease (LD) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Lyme disease (LD), historical and forecasted epidemiology as well as the Lyme disease (LD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Lyme disease (LD) market report provides current treatment practices, emerging drugs, Lyme disease (LD) market share of the individual therapies, current and forecasted Lyme disease (LD) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Lyme disease (LD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Lyme disease (LD) Disease Understanding and Treatment Algorithm

The DelveInsight Lyme disease (LD) market report gives a thorough understanding of the Lyme disease (LD) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Lyme disease (LD).

Treatment

It covers the details of conventional and current medical therapies available in the Lyme disease (LD) market for the treatment of the condition. It also provides Lyme disease (LD) treatment algorithms and guidelines in the United States, Europe, and Japan.

Lyme disease (LD) Epidemiology

The Lyme disease (LD) epidemiology division provide insights about historical and current Lyme disease (LD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Lyme disease (LD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Lyme disease (LD) Epidemiology

The epidemiology segment also provides the Lyme disease (LD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Lyme disease (LD) Drug Chapters

Drug chapter segment of the Lyme disease (LD) report encloses the detailed analysis of Lyme disease (LD) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Lyme disease (LD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Lyme disease (LD) treatment.

Lyme disease (LD) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Lyme disease (LD) treatment.

Lyme disease (LD) Market Outlook

The Lyme disease (LD) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Lyme disease (LD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Lyme disease (LD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Lyme disease (LD) market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Lyme disease (LD) market in 7MM.

The United States Market Outlook

This section provides the total Lyme disease (LD) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Lyme disease (LD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Lyme disease (LD) market size and market size by therapies in Japan is also mentioned.

Lyme disease (LD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Lyme disease (LD) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Lyme disease (LD) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Lyme disease (LD) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Lyme disease (LD) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Lyme disease (LD) emerging therapies.

Reimbursement Scenario in Lyme disease (LD)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Lyme disease (LD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Lyme disease (LD) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Lyme disease (LD) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Lyme disease (LD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Lyme disease (LD) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Lyme disease (LD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Lyme disease (LD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Lyme disease (LD) market

Report Highlights

  • In the coming years, Lyme disease (LD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Lyme disease (LD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Lyme disease (LD). Launch of emerging therapies will significantly impact the Lyme disease (LD) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Lyme disease (LD)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Lyme disease (LD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Lyme disease (LD) Pipeline Analysis
  • Lyme disease (LD) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Lyme disease (LD) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Lyme disease (LD) Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Lyme disease (LD) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Lyme disease (LD) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Lyme disease (LD) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Lyme disease (LD) market size during the forecast period (2017-2030)?
  • At what CAGR, the Lyme disease (LD) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Lyme disease (LD) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Lyme disease (LD) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Lyme disease (LD)?
  • What is the historical Lyme disease (LD) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Lyme disease (LD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Lyme disease (LD)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Lyme disease (LD) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Lyme disease (LD) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Lyme disease (LD) in the USA, Europe, and Japan?
  • What are the Lyme disease (LD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Lyme disease (LD)?
  • How many therapies are developed by each company for Lyme disease (LD) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Lyme disease (LD) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Lyme disease (LD) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Lyme disease (LD) and their status?
  • What are the key designations that have been granted for the emerging therapies for Lyme disease (LD)?
  • What are the global historical and forecasted market of Lyme disease (LD)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Lyme disease (LD) market
  • To understand the future market competition in the Lyme disease (LD) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Lyme disease (LD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Lyme disease (LD) market
  • To understand the future market competition in the Lyme disease (LD) market

Table of Contents

1. Key Insights

2. Executive Summary of Lyme disease (LD)

3. Competitive Intelligence Analysis for Lyme disease (LD)

4. Lyme disease (LD): Market Overview at a Glance

  • 4.1. Lyme disease (LD) Total Market Share (%) Distribution in 2017
  • 4.2. Lyme disease (LD) Total Market Share (%) Distribution in 2030

5. Lyme disease (LD): Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Lyme disease (LD) Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Lyme disease (LD) Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Lyme disease (LD) Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Lyme disease (LD) Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Lyme disease (LD) Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Lyme disease (LD) Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Lyme disease (LD) Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Lyme disease (LD) Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Lyme disease (LD) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Lyme disease (LD) Treatment and Management
  • 8.2. Lyme disease (LD) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Lyme disease (LD) Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Lyme disease (LD): Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Lyme disease (LD) Market Size in 7MM
  • 13.3. Lyme disease (LD) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Lyme disease (LD) Total Market Size in the United States
    • 15.1.2. Lyme disease (LD) Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Lyme disease (LD) Total Market Size in Germany
    • 15.3.2. Lyme disease (LD) Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Lyme disease (LD) Total Market Size in France
    • 15.4.2. Lyme disease (LD) Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Lyme disease (LD) Total Market Size in Italy
    • 15.5.2. Lyme disease (LD) Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Lyme disease (LD) Total Market Size in Spain
    • 15.6.2. Lyme disease (LD) Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Lyme disease (LD) Total Market Size in the United Kingdom
    • 15.7.2. Lyme disease (LD) Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Lyme disease (LD) Total Market Size in Japan
    • 15.8.3. Lyme disease (LD) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Lyme disease (LD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Lyme disease (LD) Epidemiology (2017-2030)
  • Table 2 : 7MM Lyme disease (LD) Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Lyme disease (LD) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Lyme disease (LD) Epidemiology in Germany (2017-2030)
  • Table 6 : Lyme disease (LD) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Lyme disease (LD) Epidemiology in France (2017-2030)
  • Table 8 : Lyme disease (LD) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Lyme disease (LD) Epidemiology in Italy (2017-2030)
  • Table 10 : Lyme disease (LD) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Lyme disease (LD) Epidemiology in Spain (2017-2030)
  • Table 12 : Lyme disease (LD) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Lyme disease (LD) Epidemiology in the UK (2017-2030)
  • Table 14 : Lyme disease (LD) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Lyme disease (LD) Epidemiology in Japan (2017-2030)
  • Table 16 : Lyme disease (LD) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Lyme disease (LD) Epidemiology (2017-2030)
  • Figure 2 : 7MM Lyme disease (LD) Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Lyme disease (LD) Epidemiology in the United States (2017-2030)
  • Figure 4 : Lyme disease (LD) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Lyme disease (LD) Epidemiology in Germany (2017-2030)
  • Figure 6 : Lyme disease (LD) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Lyme disease (LD) Epidemiology in France (2017-2030)
  • Figure 8 : Lyme disease (LD) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Lyme disease (LD) Epidemiology in Italy (2017-2030)
  • Figure 10 : Lyme disease (LD) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Lyme disease (LD) Epidemiology in Spain (2017-2030)
  • Figure 12 : Lyme disease (LD) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Lyme disease (LD) Epidemiology in the UK (2017-2030)
  • Figure 14 : Lyme disease (LD) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Lyme disease (LD) Epidemiology in Japan (2017-2030)
  • Figure 16 : Lyme disease (LD) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)